Los Angeles, CACIK 21116091 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
37 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Praxis Precision Medicines I | 40.0K | $11.79M | 13.7% | +40.0K | New Position |
| 2 | Xeris Biopharma Holdings Inc | 800.0K | $6.28M | 7.3% | +800.0K | New Position |
| 3 | Biomarin Pharmaceutical Inc | 100.0K | $5.94M | 6.9% | +100.0K | New Position |
| 4 |
| Amicus Therapeutics Inc |
| 360.0K |
| $5.13M |
| 6.0% |
| +360.0K |
| New Position |
| 5 | Acadia Pharmaceuticals Inc | 160.0K | $4.27M | 5.0% | +160.0K | New Position |
| 6 | Annexon Inc | 750.0K | $3.77M | 4.4% | +750.0K | New Position |
| 7 | Nuvation Bio Inc | 400.0K | $3.58M | 4.2% | +400.0K | New Position |
| 8 | Bridgebio Pharma Inc | 36.0K | $2.75M | 3.2% | +36.0K | New Position |
| 9 | Ptc Therapeutics Inc | 36.0K | $2.73M | 3.2% | +36.0K | New Position |
| 10 | United Therapeutics Corp Del | 5.5K | $2.68M | 3.1% | +5.5K | New Position |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio